ArticleComputational and structural biotechnology journal2025
Investigating and evaluating potential antigen binding sites for monoclonal anti-HER2 antibodies: The LightDock approach.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Structural Remodeling of TCR-HLA-DQ8 Recognition by a β-Cell Stress-Associated C19S Insulin Neoepitope in Type 1 Diabetes.International journal of molecular sciences · 2026Article
- Exploring the Binding Specificity of Siglec-Derived Peptides to Human Primary Amine Oxidase Using an Integrative Approach to Ligand Epitope Mapping.Computational and structural biotechnology journal · 2026Article
- AlphaFold in protein structure and function prediction.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies targeting HER2, a receptor overexpressed in certain cancer cells, have greatly improved the treatment of HER2-positive cancers. In addition, anti-HER2 antibodies play a critical role in diagnostic applications, enabling accurate detection of HER2 expression levels. Advancing antibody-based therapies and diagnostic tools require a thorough understanding of binding interactions, but it remains challenging due to complex antibody protein structure and its flexibility, particularly within their complementarity-determining regions. In this study we utilized LightDock, a molecular docking tool simulating protein-protein interactions which can incorporate flexibility that allows the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.